Real world Nuvaxovid COVID-19 vaccine safety profile after 100,000 doses in Australia, 2022-2023
View ORCID ProfileHazel J Clothier, Claire Parker, John H Mallard, View ORCID ProfilePaul Effler, View ORCID ProfileLauren Bloomfield, Dale Carcione, View ORCID ProfileJim P Buttery
doi: https://doi.org/10.1101/2024.03.17.24304409
Hazel J Clothier
1Epi-Informatics, Centre for Health Analytics, Melbourne Children’s Campus, Melbourne, Australia
2Epi-Informatics Group and SAEFVIC Epidemiology, Surveillance and Signal Detection, Murdoch Childrens Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Victoria, Australia
4Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia
Claire Parker
5Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Australia
6Immunisation Service, Perth Children’s Hospital, Nedlands, Western Australia, Australia
John H Mallard
1Epi-Informatics, Centre for Health Analytics, Melbourne Children’s Campus, Melbourne, Australia
2Epi-Informatics Group and SAEFVIC Epidemiology, Surveillance and Signal Detection, Murdoch Childrens Research Institute, Melbourne, Australia
Paul Effler
5Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Australia
Lauren Bloomfield
5Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Australia
Dale Carcione
5Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Australia
Jim P Buttery
1Epi-Informatics, Centre for Health Analytics, Melbourne Children’s Campus, Melbourne, Australia
2Epi-Informatics Group and SAEFVIC Epidemiology, Surveillance and Signal Detection, Murdoch Childrens Research Institute, Melbourne, Australia
3Department of Paediatrics, University of Melbourne, Victoria, Australia
7Infectious Diseases Unit, Royal Children’s Hospital Melbourne, Victoria, Australia
Article usage
Posted March 18, 2024.
Real world Nuvaxovid COVID-19 vaccine safety profile after 100,000 doses in Australia, 2022-2023
Hazel J Clothier, Claire Parker, John H Mallard, Paul Effler, Lauren Bloomfield, Dale Carcione, Jim P Buttery
medRxiv 2024.03.17.24304409; doi: https://doi.org/10.1101/2024.03.17.24304409
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (640)
- Anesthesia (170)
- Cardiovascular Medicine (2433)
- Dermatology (208)
- Emergency Medicine (383)
- Epidemiology (11861)
- Forensic Medicine (10)
- Gastroenterology (706)
- Genetic and Genomic Medicine (3807)
- Geriatric Medicine (353)
- Health Economics (643)
- Health Informatics (2449)
- Health Policy (947)
- Hematology (347)
- HIV/AIDS (802)
- Medical Education (375)
- Medical Ethics (105)
- Nephrology (406)
- Neurology (3562)
- Nursing (201)
- Nutrition (534)
- Oncology (1851)
- Ophthalmology (542)
- Orthopedics (224)
- Otolaryngology (291)
- Pain Medicine (235)
- Palliative Medicine (68)
- Pathology (453)
- Pediatrics (1050)
- Primary Care Research (426)
- Public and Global Health (6232)
- Radiology and Imaging (1309)
- Respiratory Medicine (841)
- Rheumatology (385)
- Sports Medicine (328)
- Surgery (413)
- Toxicology (51)
- Transplantation (174)
- Urology (148)